About comera life sciences holdings inc - CMRA
Comera Life Sciences Holdings, Inc. engages in developing medicines. It applies a deep knowledge of formulation science and technology to transform essential biologic medicines. The firm's approach is to provide patients with the freedom of self-injectable care, reduce institutional dependency and to put patients at the center of their treatment regimen. The company was founded on January 31, 2022 and is headquartered in Woburn, MA.
CMRA At a Glance
Comera Life Sciences Holdings, Inc.
12 Gill Street
Woburn, Massachusetts 01801
| Phone | 1-617-871-2101 | Revenue | 633.10K | |
| Industry | Pharmaceuticals: Major | Net Income | -18,004,098.00 | |
| Sector | Health Technology | Employees | 13 | |
| Fiscal Year-end | 12 / 2023 | |||
| View SEC Filings |
CMRA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 20.308 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.562 |
| Enterprise Value to Sales | 25.584 |
| Total Debt to Enterprise Value | 0.048 |
CMRA Efficiency
| Revenue/Employee | 48,700.154 |
| Income Per Employee | -1,384,930.615 |
| Receivables Turnover | 18.447 |
| Total Asset Turnover | 0.011 |
CMRA Liquidity
| Current Ratio | 0.606 |
| Quick Ratio | 0.606 |
| Cash Ratio | 0.386 |
CMRA Profitability
| Gross Margin | 66.768 |
| Operating Margin | -1,653.765 |
| Pretax Margin | -2,843.791 |
| Net Margin | -2,843.791 |
| Return on Assets | -32.396 |
| Return on Equity | -37.275 |
| Return on Total Capital | 1,886.569 |
| Return on Invested Capital | -37.228 |
CMRA Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -81.214 |
| Total Debt to Total Assets | 20.795 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -12.606 |